AbbVie price target lowered to $191 from $196 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on AbbVie to $191 from $196 and keeps an Overweight rating on the shares. Questions on 2025 estimates likely drove the recent move down in shares despite the company posting a beat and raise quarter, but the firm sees key growth drivers such as Skyrizi, Rinvoq and aesthetics as on track, the analyst tells investors in a Q1 earnings recap note.